The neuropsychological characterization of aggressive behaviour in children and adolescents with Conduct Disorder or Oppositional Defiant Disorder (CD/ODD) - The neuropsychological features of aggressive behaviour in children and adolescents with CD/ODD)

RADBOUD UNIVERSITY MEDICAL CENTER0 sites160 target enrollmentSeptember 9, 2021

ConditionsAggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD)MedDRA version: 21.1Level: LLTClassification code 10037183Term: Psychic disturbanceSystem Organ Class: 100000004873 Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]

DrugsRisperdal Abilify Strattera Medikinet

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Aggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD)
Sponsor: RADBOUD UNIVERSITY MEDICAL CENTER
Enrollment: 160
Status: Active, not recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

September 9, 2021

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

RADBOUD UNIVERSITY MEDICAL CENTER

Eligibility Criteria

Inclusion Criteria

•ODD/CD GROUP:
•\-IQ \= 80 (Wechsler IQ scale, within the last two years before enrolment);
•\-Age between 10 years and 17 years and 10 month at the screening visit
•\-Diagnosis of ODD or CD, based on the DSM\-5 including the semi\-structured K\-SADS\-PL interview;
•\-Aggression in the clinical range, T \= 70 on the aggression or delinquency subscale of the Teacher Report Form (TRF), Youth Self Report (YSR), or Child Behaviour Checklist (CBCL); or score \= 27 on the Nisonger\-CBRF D\-Total (composite of Disruptive Behavior Disorder subscales);
•\-The patient is eligible to be treated with a pharmacological therapy based on previous medical and instrumental cardiological assessments (personal and family cardiological history, ECG within the last six months; see 5\.2\.1\.1\) and based on previous blood chemistry (performed within the last six months), current physical and neurological examination;
•\-Patient is drug\-naive for psychotropic medications or off any psychotropic medication (Psychostimulants, antipsychotics, SNRI, mood stabilizers or antidepressant) within the last six months.
•\-If the patient is a girl who is sexually active and of childbearing potential (WOCBP: Women of Childbearing Potential, defined as females aged \=10 years old and younger girls who, at the discretion of the investigator, are deemed to be of reproductive potential), must have a negative urine pregnancy test at the Screening visit and at Baseline visit prior to randomization for phase III. The urine pregnancy test will be repeated, each week, during the randomised single\-blind, placebo controlled, single dose, cross\-over, acute challenge phase. The inclusion of WOCBP will require, throughout the study period, the use of condom and one of the following highly effective contraceptive measures: intrauterine devices, hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring). ¿Other acceptable contraception methods are: ¿double barrier methods (e.g., condoms and diaphragms with spermicidal gel or foam).
•\-Subjects’ parents/legal guardians must provide and sign informed consent documents; patients must provide informed consent, and sign consent or assent documents if capable and permitted according to the legal requirements in the country;
•\-Patients meeting criteria for comorbid ADHD, Depression, Anxiety or PTSD (as to the clinical judgment of the investigator) will not be excluded from study participation.

Exclusion Criteria

•ODD/CD GROUP:
•\-IQ \< 80 (Wechsler IQ scale, within the last two years before enrolment);
•\-The subject has a primary DSM\-5 diagnosis of schizophrenia\-related disorders, schizophrenia, bipolar disorder, Autistic Spectrum Disorder, depression or anxiety;
•\-The subject had any psychotropic medications (Psychostimulant, antipsychotics, SNRI, antidepressant, mood stabilizers) within the last six months before screening visit;
•\-The subject is pregnant or nursing;
•\-The subject has a body weight \< 30 Kg
•\-The subject has any acute or unstable medical condition that, in the opinion of the investigator, would compromise participation in the study. The patient will be excluded if presents with one or more of the following conditions: neurological disorder, other psychiatric disorder, cardiovascular disease, seizure disorder on encephalopathy, congestive heart failure, cardiac hypertrophy, arrhythmia, bradycardia (pulse\<50bpm), respiratory disease, hepatic impairment or renal insufficiency, metabolic disorder, endocrinological disorder, gastrointestinal disorder, haematological disorder, infectious disorder, any clinically significant immunological condition, dermatological disorder, congenital or juvenile glaucoma or is at risk of acute narrow\-angle glaucoma
•\-The subject has a history of severe allergies to medications, in particular hypersensitivity to neuroleptics, or of multiple adverse drug reactions, or the patient has any contraindications to the use of the study drugs as following:
•Metilphenidate and Atomoxetine are contraindicated in patients known to be hypersensitive to these drugs or other components of the products; in patients with glaucoma; during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibition; in patients with severe hypertension, angina pectoris, cardiac arrhythmias, heart failure, recent myocardial infarction, hyperthyroidism or thyrotoxicosis.
•Risperidone is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the formulation.